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BACKGROUND: Aromatic plants are usually used in traditional medicine as antimicrobial agents. Their  
essential oils, isolated by hydro-steam distillation, have been known since antiquity to posses’ antimicrobial 
property. The objective of this study was to formulate topical antimicrobial agents for the treatment of human skin 
diseases from myrtle and clove essential oils.  
METHODS: The plant were collected from Bale Zone, North Shewa Zone and Botanical Garden of Department of 
Drug Research, Ethiopian Health and Nutrition Research Institute on Augest to October, 2007. Eessential oils of 
both plants were collected by hydro-steam distillation in the Formulation Research Laboratory of Department of 
Drug Research. After the preparation of 1% Eugenia caryophyllus and 4% Myritus communis essential oil 
formulation in five different formulation bases; the antimicrobial activity were detected in the Microbiology 
Laboratory by using diffusion assay methods. 
RESULTS: In the assayed antimicrobial activity topical formulation of 1% Eugenia caryophyllus and 4% Myritus 
communis essential oils have shown significantly high antimicrobial activity against: Staphylococcus aureus, 
Streptococcus pneumonia, Pseudomonas aeruginosa, Aspergillus niger, Aspergillus flavus, Trachophyton 
mentagraphyte, Trachophyton vericusom, Microsporum cannis, Candida albicans, Cryptococcus neoformans than 
commonly used drugs. Both topical formulations were more effective in the hydrophilic bases than the lipophilic 
bases used in the study. 
CONCLUSION: Our results of topical formulation in hydrophiic ointment or macrogol blend base support the 
concept that essential oil may be useful for the treatment of microbial infection. Therefore, we suggest that the 
topical formulation of these oils can be used as alternative drugs for the treatment of skin disease. However, skin 
sensitivity study of the topical formulations must be performed to ensure their safety.  






Skin disease that are caused by bacteria and fungal 
strains have become prevalent in the world, due to the 
emergence of disease such as HIV/AIDS, compounded 
with increased use of common recreational areas like 
swimming (1,2). Due to different factors, these diseases 
are more common in developing countries where 
Ethiopia is not exception (3). As a result of failure to 
treat skin diseases by the available antimicrobial agents 
due emergence of emergence of resistant  
microorganisms; now a days many researchers focused 
on the search for new drug from natural products (4,5). 
 Because of their long history of use in the treatment 
of different human diseases, most of the herbal medicines 
are believed to be safer and effective than synthetic 
drugs. According to WHO, herbal medicines serve the 
health needs of about 80% of the world population (6). 
Aromatic plants especially their essential oil and mixture 
of natural compound isolated by distillation, were among 
these herbs that have been used as traditional medicine to 
treat bacterial and fungal diseases (7). Essential oils are 
volatile products of aromatic plants secondary 
metabolism, normally formed in special cell or group of 
cells found in many leaves and stems. It is concentrated 
or stored either in particular region of the plant or in 
various organs in the same plants (8). 
Previous studies showed that essential oils of aromatic 
plants have antimicrobial activity against bacterial and 
fungal pathogens (9-12). Their antimicrobial activity is 
attributed to the presence of small terpenoid and phenolic 
compounds (phenolic acids, polyphenols and flavonoids) 
which are related to their lipophilic character that leads to 
accumulation  on membrane and to the subsequent 
membrane associated event such as energy depletion (8). 
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In Ethiopia various aromatic plants having different 
essential oils, are being used for aroma-treatment 
(fumigation) of diseases (13). Myritus communis and 
Eugenia caryophillata were from these aromatic plants 
that have been used for the treatment of microbial 
diseases in Ethiopia (13). Essential oils of these aromatic 
plants contain reported major compounds that were 
active against different bacterial and fungal strains. 
Myritus communis contain α-pinene, limonene and 1,8-
cineole and Eugenia caryophillata contain euginol and 
eugenyl acetate (8,14,15). 
 Even though, various studies showed the potentials 
of these essential oils to be an important source of 
biologically active compounds useful for the treatment of  
microbial diseases; no study have been conducted yet on 
its topical formulation of these plants (14, 15). 
  The objective of the present study was to fomulate 
effective antimicrobial agents from myrtle and clove 
essential oils, which can serve as topical antimicrobial 
agents for the treatment of human skin diseases caused 
by bacterial and fungal strains.   
 
MATERIALS AND METHODS 
 
Study area and Period: Plants were collected from from 
Bale Zone, North Shewa Zone and from botanical garden 
of Department of Drug Research, Ethiopian Health and 
Nutrition Research Institute, Ethiopia in Augest-
October,2007. The identities of the plants were 
taxonomically identified and the samples were deposited 
in the Department of Drug Research Herbarium. The 
essential oils of these plants were extracted in November, 
2007 in the Formulation Research Laboratory of 
Department of Drug Research. After preparation of 
Topical formulation, the in vitro experimental study or 
antimicrobial assay was conducted in the Department of 
Drug Research, Ethiopian Health and Nutrition Research 
Inistitute from December, 2007 to March, 2008.   
 
Preparation of Topical Formulations:  Essential 
oils of the identified plants were extracted by hydro-
distillation of the plant material. The oils were separated 
from the aqueous layer by using a separatory funnel and 
dehydrated with anhydrous sodium sulphate and stored in 
clean, dark brown bottles. Cetostearyl alchol, Liquid 
paraffin, Hard paraffin, Propylene Glycol, Stearyl 
alcohol, and Wool fat  (Sigma-Aldrich Chemie GmbH, 
Steinheim, Germeny), PEG 4000 and PEG (BDH, Poole, 
England), Sodium lauryl sulfate (Labort Fine Chem. Pvt. 
Ltd., India) and White soft paraffin USP (Ethiopian 
Pharmaceutical Manufacturing, Addis Ababa, Ethiopia) 
were used in the preparation. 
Topical formulation containing 1%v/w Eugenia 
caryophillata essential oil and 4%v/w Myritus communis 
essential oil were prepared separately in five different 
formulation bases. Topical formulations containing 
2%v/w Eugenia caryophillata and 8% v/w Myritus 
communis oils were prepared in the three lipophilic 
ointment bases (Table 1). 
 Control Antimicrobial Formulations: Topical 
formulations of Fuciderm 2% Cream (Delta Ltd, Lot: 28, 
Syria) and Mycoril 1% Cream (Remedica Ltd, Lot: 
IMAPT 33989) were used in the study as a positive 
control for bacterial and fungal topical treatment, 
respectively. 
 Test organism: The following bacterial and fungal 
strains were used in the study: Staphylococcus aureus 
(ATCC or American Type Culture Collection 25923 and 
clinical isolate), Pseudomonas aeruginosa (ATCC 27853 
and clinical isolate) and Streptococcus pyogen (ATCC 
19615 and clinical isolate), Aspergilus niger (ATCC 
10535 and clinical isolate), Aspergilus flavus (ATCC 
13697 and clinical isolate), Trichophyton mentagraphyte 
(ATCC 18748 and clinical isolate), Trichophyton 
verrucosum (clinical isolate), Microsporum cannis 
(clinical isolates), Candida albican (clinical isolate), and 
Cryptococcus neoformans (clinical isolate). All the 
clinical isolates were taken from sample of patients with 
skin disorder are stored at the Bacteriology and 
Mycology Laboratory, Ethiopian Health and Nutrition 
Research Institute. All the organisms were periodically 
characterized and maintained in the Microbiology 
Laboratory, Department of Drug Research during the 
study period. 
Test for Antimicrobial Activity: An agar cup diffusion, 
long period methods were used as antimicrobial activity 
tests (16,17). Fiffteen millileter of molten and cooled 
(45
0
C) agar were added to sterile petri dish (90mm) and 
allowed to solidify. Three equidistant holes 10mm apart 
from the edge of the plate were formed in the agar by 
removing the plug made with sterile cork borer (10mm). 
Using of 5 ml syringe with a gauge needle, weighed 
amounts (0.1 ml ≈0.2 g) of a designated topical agent 
were added to each well. A volume of 0.2 ml suspension 
of overnight Nutrient broth (Oxoid Ltd, UK) culture 
having standard turbidity of the respective bacteria and 
overnight Sabouraud Dextrose broth (Oxoid Ltd, UK)  
culture and young culture of respective fungus were used 
as a test organisms inoculated into 7 ml of molten and 
cooled (45 °C) Muller-Hinton agar (Oxoid Ltd, UK)  for 
that of bacteria and Sabouraud Dextrose Agar (Oxoid 
Ltd, UK) for fungi. The agar suspension of organisms 
was thoroughly mixed by WHIRLI MIXER
TM
 (Nickel 
ELECTRO, Ltd., AVON) and poured onto the previously 
prepared test plate containing antimicrobial agents. After 
the plate solidified for 2-3 minutes, they were inverted 
and allowed to stand for 1 hour at room temperature and 
incubated at 37
0
C (bacteria) and 25
0
C (fungi) for 24 
hours in case of bacteria and yeasts; for 48 hours for 
molds and up to five days for dermatophytes. After 




incubation the diameter of zones of inhibition (excluding 
cup size) was measured and compared with negative 
(formulation bases with out drug) controls and positive 
(standard topical formulation or drugs) controls. Results 
were recorded as presence or absence of zone of 
inhibition (16). Both inhibitory zone diameter around the 
cups or well containing the formulations and percentage 
of relative inhibition zones were recorded as 
antimicrobial activity of the formulation. The absences of 
inhibition zones were recorded as zero. The test was 
performed in triplicate to insure reliability of the results.  
 
  Percentage of Relative inhibiton zone diameter 
 
 %RIZD is percentage of rilative inhibition zone 
diameter, IZD is inhibition zone diameter. These value 
would indivate the antimicrobial potency of the topical 
preparations by companceting the activity due to the 
bases in the formulation and at the same time will 
compare the activity of this topical preparation with that 
of commenly used drugs.   
RESULTS  
 
Essential oils were extracted from Eugenia caryophillata 
and Myritus communis with the yield of 10.8 % and 0.5% 
based on the weight of the plant used for extraction, 
respectively.  Topical preparation containing 1% Eugenia 
caryophillata and 4% Myritus communis essential oils 
exhibited antimicrobial activity. Topical formulation of 
both essential oils in hydrophilic ointment bases 
exhibited the highest antimicrobial activity, followed by 
macrogol-blend ointment bases. One percent E. 
caryophillata and 4% M. communis essential oils 
preparation in macrogol cream base, simple ointment 
bases and white soft paraffin showed no inhibition of 
microbial growths. Even at  2% E. caryophillata and 8% 
M. communis essential oils preparation in macrogol 
cream base, simple ointment bases and white soft 
paraffin were performed still no inhibition of microbial 
growth. However, 1% E. caryophillata and 4% M. 
communis preparation in hydrophilic and macrogol-blend 
ointments inhibited the growth of bacteria and fungi 
(Table 2 and 3). 
 
 
Table 1. Formulation bases used in the study for the topical preparation of the essential oils, Ethiopian Health and 
Nutrition Research Inistitute, 2008. 
 
Codes  Bases Compositions Proportions (%) 
BASE 1 Macrogol Cream Cetomacrogol emulsifying wax 9 
Liquid paraffin 6 
White soft paraffin 15 
Water 70 
BASE 2 Hydrophilic 
ointment 
Sodium lauryl sulfate 1 
Propylene Glycol 12 
Stearyl alcohol 25 
White soft paraffin 25 
Water 37 
BASE 3 Macrogol blend 
ointment 
PEG 4000 20 
PEG 600 80 
BASE 4 Simple ointment Stearyl alcohol 5 
Hard paraffin 5 
Wool fat 5 
White soft paraffin 85 

















Table 2. Antibacterial inhibition zone diameter of topical formulations by excluding the size of the borer, Ethiopian  
              Health and Nutrition Research Inistitute, 2008. 
Test sample Code Inhibition Zone Diameter (mm) 
  Standard bacterial strain Clinical Isolate strains 
  Sa Stp. Pa Sa Stp Pa 
1% Eugenia caryophyllatas in 
Macrogol cream base Base 1 0 0 0 0 0 0 
Hydrophilic ointment Base 2 20 15 6 18 14 6 
Macrogol-blend ointment Base 3 16 14 7 14.5 13 5 
Simple ointment Base 4 0 0 0 0 0 0 
White soft paraffin  Base 5 0 0 0 0 0 0 
4% Myritus communis in        
Macrogol cream base Base 1 0 0 0 0 0 0 
Hydrophilic ointment Base 2 22 16 9 20 20 6.3 
Macrogol-blend ointment Base 3 10 5 3 9 5 3 
Simple ointment Base 4 0 0 0 0 0 0 
White soft paraffin  Base 5 0 0 0 0 0 0 
Negative controlsa        
Macrogol cream base N1 0 0 0 0 0 0 
Hydrophilic ointment N2 2 5 0 2 4 0 
Macrogol-blend ointment N3 0 0 0 0 0 0 
Simple ointment N4 0 0 0 0 0 0 
White soft paraffin  N5 0 0 0 0 0 0 
Positive control        
Fuciderm 2% cream P1 23.3 15 6 20.6 13 4 
Sa, Staphylococcus aureus, Stp, Streptococcus pyogen, pa, Pseudomonas aeruginosa 
 
Table 4. Antimicrobial activity profile indicated in Percentage of Rilative Inhibition Zone diameter, Ethiopian Health 
and Nutrition Research Inistitute, 2008. 
 
Test sample Code              Inhibition Zone Diameter (mm) 
Standard  strain Clinical Isolate strains 
Sa Stp Pa Sa Stp Pa 
1% Eugenia caryophyllatas in 
Hydrophilic ointment Base 2 80.7 66.7 100 77.7 76.9 150 
Macrogol-blend ointment Base 3 71.7 60 116 72.5 100 125 
4% Myritus communis in 
Hydrophilic ointment Base 2 89.7 73.3 150 90 123 156 
Macrogol-blend ointment Base 3 44.8 33.3 50 87.1 38.5 75 
1% Eugenia caryophyllatas in 
  An Af. Tm An Af Tm TV Mc Ca Cn 
Hydrophilic ointment Base 2 246 159 145 163 106 105 125 112 81 194 
Hydrophilic ointment Base 2 246 159 145 163 106 105 125 112 81 194 
Macrogol-blend ointment Base 3 173 132 136 173 97 125 125 112 13
5 
171 
4% Myritus communis 
Macrogol-blend ointment Base 3 100 64.7 90.9 100 67 75 85 62 75 88 
Hydrophilic ointment Base 2 164 137 81.8 155 100 80 85 76 75 119 
Macrogol-blend ointment  Base 2 100 64.7 90.9 100 67 75 85 62 75 88 
Sa, Staphylococcus aureus, Stp, Streptococcus pyogen, pa, Pseudomonas aeruginosa An, Aspergilus niger, Af, 
Aspergilus flavus, Tm, Trichophyton mentagraphyte, Tv, Trichophyton verrucosum, Mc, Mycrosporum cannis, Ca, 








Table 3. Antifungal inhibition zone diameter of topical formulation by excluding the size of the borer, Ethiopian 
Health and Nutrition Research Inistitute, 2008. 
Test sample Codes Inhibition Zone Diameter (mm) 
Standard fungi 
strains 
Clinical Isolate of fungi strains 
An Af. Tm An Af Tm Tv Mc Ca Cn 
1% Eugenia caryophyllatas in 
Macrogol cream  Base 1 0 0 0 0 0 0 0 0 0 0 
Hydrophilic ointment Base 2 33 30 36 22 23 30 35 25 17 34 
Macrogol-blend ointment Base 3 19 22.5 30 19 18 25 25 19 21.6 27.3 
Simple ointment Base 4 0 0 0 0 0 0 0 0 0 0 
White soft paraffin  Base 5 0 0 0 0 0 0 0 0 0 0 
4% Myritus communis in 
Macrogol cream  Base 1 0 0 0 0 0 0 0 0 0 0 
Hydrophilic ointment Base 2 24 26.3 32 21 22 25 27 19 16 21 
Macrogol-blend ointment Base 3 11 11 20 11 12 15 17 10.6 12 14 
Simple ointment Base 4 0 0 0 0 0 0 0 0 0 0 
White soft paraffin  Base 5 0 0 0 0 0 0 0 0 0 0 
Negative controls 
Macrogol cream  N1 0 0 0 0 0 0 0 0 0 0 
Hydrophilic ointment N2 6 3 14 4 4 9 10 6 4 3 
Macrogol-blend ointment N3 0 0 0 0 0 0 0 0 0 0 
Simple ointment N4 0 0 0 0 0 0 0 0 0 0 
White soft paraffin  N5 0 0 0 0 0 0 0 0 0 0 
Positive control            
Mycoril 1% cream P1 11 17 22 11 18 20 20 17 16 16 
 
An, Aspergilus niger, Af, Aspergilus flavus, Tm, Trichophyton mentagraphyte, Tv, Trichophyton verrucosum, Mc, 
Mycrosporum cannis, Ca, Candida albican, Cn, Cryptococcus neoformans 
 
The percentage of relative inhibition of bacterial and 
fungal growth by compensating the effect of vehicle was 
tested.  Accordingly, Myritus communis preparation in 
hydrophilic ointment showed higher activity against the 
standard organism of P. auroginosa, A. niger, A. flavus 
and clinical isolates of P. auroginosa, S. pneumonia, A. 
niger and C. neoformans when compared to commonly 
used drugs. One percent Eugenia caryophillata in 
hydrophilic and macrogol-blend ointments also showed 
higher activity against P. auroginosa clinical isolate and 
standard organism respectively. When compared to the 
tested drugs, higher activities were observed in 1% 
Eugenia caryophillata in hydrophilic and macrogol-blend 
ointments preparations against all standard fungal strain 
and all clinical isolates except C. albicans and A. flavus 
isolates, respectively. Comparable results with the 
antibiotics used were observed in 1% Eugenia 
caryophillata formulation in hydrophilic and macrogol-
blend ointments against standard  P. auroginosa and 
clinical isolates of P. auroginosa, S. pneumonia, 
respectively. Similarly,  4% Myritus communis 
preparations in macrogol-blend and hydrophilic 
ointments inhibited growth of standard A. niger, isolates 
of A. niger and A. flavus. The over all highest percentage 
of inhibition was recorded against standard A. niger 
followed by isolates of C. neoformans in hydrophilic 
prepation and then against both standard and isolates of 
A. niger in macrogol-blend ointment preparation of 1% 











Eugenia caryophillata essential oil contain 78% Eugenol 
and 13% Eugenyl acetate and Myrtus communis contain 
56% α-pinene and 33% 1,8-cineole as a major 
component, which were mainly responsible for their 
antimicrobial activity (14,15). Besides these major 
components, the variation in antimicrobial activity of the 
essential oils of the same plant in different formulation as 
indicated in table 2, 3, 4 were due to the nature of the 
base it is formulated in which has considerable effect on 
its efficacy (18,19). Factors that affect the release of a 
bioactive component from the base include its affinity to 
the base (18,19). Hydrophilic bases have less affinity for 
the oils while the lipophilic bases have higher affinity for 
oils than the agar medium used. 
 The result showed, both macrogol-blend and 
hydrophilic ointment base topical formulations of both 
essential oils have markedly higher activity when 
compared to the essential oil formulations in lipophilic 
bases (macrogol cream, simple ointment, and white soft 
paraffin) which exhibited no activity. These variation 
could be attributed to the lipophilic affinity of the oils for 
paraffin found in macrogol cream base, simple ointment 
base and white soft paraffin; which impairs the release of 
bioactive constituents of the essential oils into the more 
hydrophilic agar media. In addition to their hydrophilic 
affinity, the intrinsic antimicrobial property of sodium 
luaryl sulphate may have contributed for the higher 
antimicrobial activity of essential oil topical formulations 
in hydrophilic ointment bases. Whereas, the bland 
inherent activity and higher hydrophilic affinity of 
macrogol-blend ointment base compared to the agar 
media might have contributed for its higher antimicrobial 
activity. The effect of sodium luaryl sulphate were 
compensated in the expresion of percentage of relative 
inhibition (see the Mathimatical expresion for the 
calculation of percentage of relative inhibition).  
 This study showed above 100% relative inhibition 
of microbial growths indicating that  the topical 
preparation of the essential oils had greater inhibition 
zone diameter (IZD) than the commonly used  
antibiotics.  The percentage of relative inhibition 
diameter is inversily proportional to the inhibition zone 
diameter of the commertial antibiotic while directly 
proportional to that of the test sample.  
 This study indicated, in some cases percentage of 
relative inhibition zone diameters of both essential oils 
formulation on the bacterial clinical isolates exceed that 
of the standard organism. This may be due to the higher 
sensitivity patterns of the bacterial clinical isolates to that 
of the topical formulations than to commonly used drugs, 
while the standard organism seems less resistant to the 
commonly used drugs. Unlike bacterial clinical isolates, 
all standard organisms of fungal strains were more 
susceptible to both formulations. 
 The present study confirmed that the hydrophilic 
topical formulation of 1%v/w Eugenia caryophillata 
essential oil and 4%v/w Myritus communis posses strong 
in-vitro antimicrobial activity against all tested skin-
disease causing organisms. The study also showed that 
the topical formulations had better antimicrobial activity 
compared to the tested drugs 
In conclusion, our study showed that the essential oils of 
E. caryophillata and M. communis had better 
antimicrobial activity than control drugs in vitro. Because 
of their natural origin in which peoples can find it 
comforting, low risk of the microbial resistance to the 
mixture of the components that make up the oil having 
apparent diversity of antimicrobial mechanisms and their 
remarkable antimicrobial activity, we recommend the use 
of topical formulations of E. caryophillata and M. 
communis essential oils as an alternative treatment of 
skin diseases disorders after the toxicological and skin 
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